CareDx to Acquire Oncology Diagnostics Company Naveris for $160 Million
CareDx will acquire Naveris for $160 million, adding a Medicare-reimbursed liquid biopsy platform for viral-mediated cancer monitoring to its precision medicine portfolio.
Latest Articles
Editor's Top Picks
Policy and Payment Gaps Limit Access to Critical Diagnostic Testing
A new analysis finds that policy and payment gaps are limiting access to diagnostics, with nearly half the world lacking adequate testing and reimbursement lagging behind advances in precision therapies.
Be the First to Know What’s Next in the Lab
Every week, we dig into the biggest shifts, breakthroughs, and tech transforming clinical diagnostics. Straightforward, insightful, and always relevant.Critical Resources
Diagnostic Innovations
Routine Lab Tests May Help Identify Physical Effects of PTSD
Researchers at Mass General Brigham identified 16 routine lab markers, including cholesterol and glucose, linked to PTSD’s physical effects, suggesting standard tests could aid in assessing the disorder’s multi-organ impact.
Equipment & Supply Spotlight
Thermo Fisher Launches Thermal Cycler for Workflow Flexibility and Lab Automation
The system features advanced thermal technology and modular block configurations to support complex molecular biology protocols.
News, Know-How & Standards
Disease Detection & Understanding
New Endometrial Sampling Device Receives FDA Clearance for Cancer Detection
Utepreva LLC has received FDA clearance for its single-use endometrial sampler, which employs three sampling mechanisms to improve tissue yield for cytologic and molecular analysis in early endometrial cancer detection.
